Panmure Gordon disclosed Hutchison China Meditech Ltd (LON:HCM), boosting its stock price target to 2,630.00GBX earlier today
- Updated: September 16, 2016
Reporting a possible upside of 0.43%, Panmure Gordon bumped the target stock price of Hutchison China Meditech Ltd (LON:HCM) to 2,630GBX.
Only yesterday Hutchison China Meditech Ltd (LON:HCM) traded 1.63% higher at 1,835.00GBX. The company’s 50-day average is 1,842.77GBX and its two hundred day moving average is 1,893.88GBX. The last stock price close is down 1.52% from the two hundred day moving average, compared with the S&P 500 which has decreased -0.01% over the same period. Trade volume was was down over the average, with 1,881 shares of HCM changing hands under the typical 11,074 shares..
With a market cap of 0.0 GBX, Hutchison China Meditech Ltd has a price-earnings of 0 with a 52 week low of 1,612.50GBX and a one-year high of 2,896.60GBX.
A total of 2 brokerages have issued a ratings update on the stock. Zero rate the stock a strong buy, 0 rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with a 12-month target of 19.00GBX
About Hutchison China Meditech Ltd (LON:HCM)
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, and manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.